Key facts
- Florey Biosciences’s last known valuation is $5.4M (Apr 2025).
- It has raised $1.4M across 1 recorded rounds; the latest was Seed Round ($1.4M) in Apr 2025.
- Notable investors include Wyss Institute at Harvard University.
- Florey Biosciences has filed 1 Form D with the SEC, most recently Apr 2025 ($1.4M sold to 1 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Florey Biosciences
Funding rounds
1 roundsAbout Florey Biosciences
Developer of engineered probiotics designed to support and improve the human microbiome. The company offers engineered probiotics developed as medical food for the dietary management of antibiotic perturbations of the gut microbiome, enabling patients to ensure the proper function of their digestive, metabolic, and immune systems.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2024
- Employees
- 3
- Website
- floreybiosciences.com/
- Ownership
- Privately Held (backing)
Florey Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Florey Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Florey Biosciences in its N-PORT filings yet. We sweep new filings monthly.